MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

NCT06177028 PHASE2 NOT_YET_RECRUITING

This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as to changes in the relationship between the subject and study partner that might occur with the initiation of treatment and expectation of improvement in motor symptoms or cognition. Changes in subject/study partner interactions can impact subject mood and might introduce biases that cannot be quantified. The double-blind use of placebo will also prevent bias in the clinical and scientific assessments.

Details

Lead sponsor	St. Joseph's Hospital and Medical Center, Phoenix
Phase	PHASE2
Status	NOT_YET_RECRUITING
Enrolment	45
Start date	Sun Jun 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jan 02 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Cognitive Impairment, Mild
• Cognitive Dysfunction
• Amyloid Plaque
• Neurodegenerative Disease, Hereditary
• Inflammation, Brain

Interventions

• Lenalidomide 10 mg